Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RS BioTherapeutics Enters Into License Agreement With Synthonics for First Investigational Compound","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RS Biotherapeutics Reports Positive Results From Proof-of-Concept Trial for First Investigational Compound","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"RS BioTherapeutics Secures $3 Million Seed II Round of Funding","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Recipharm AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RS BioTherapeutics Selects Recipharm as Product Characterization Partner","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RS BioTherapeutics and National Institutes of Health Execute Research Collaboration Agreement to Evaluate Prevention and Treatment of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by RS BioTherapeutics

    Menu

    RS BioTherapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              RS BioTherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RS BioTherapeutics and National Institutes of Health Execute Research Collaboration Agreement to Evaluate Prevention and Treatment of Idiopathic Pulmonary Fibrosis

              Details:

              The collaboration aims to assess the anti-inflammatory and anti-fibrotic potential of RS BioTherapeutics’ lead compound, RSBT-001, an investigational semi-synthetic cannabidiolic acid complex, in a preclinical pulmonary fibrosis model.

              Lead Product(s): Cannabidiolic Acid Complex

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RSBT-001

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Institute on Alcohol Abuse and Alcoholism

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration August 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RS BioTherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RS BioTherapeutics Selects Recipharm as Product Characterization Partner

              Details:

              Product characterization is an important next step for RSBT-001 before filing an Investigational New Drug (IND) application with the FDA for the treatment of chronic obstructive pulmonary disease (COPD).

              Lead Product(s): RSBT-001

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RSBT-001

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Recipharm AB

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership November 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RS BioTherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RS BioTherapeutics Secures $3 Million Seed II Round of Funding

              Details:

              RSBT-001 is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases.

              Lead Product(s): Cannabidiolic Acid Complex

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RSBT-001

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Synthonics

              Deal Size: $3.0 million Upfront Cash: Undisclosed

              Deal Type: Financing September 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RS BioTherapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RS Biotherapeutics Reports Positive Results From Proof-of-Concept Trial for First Investigational Compound

              Details:

              The data from the proof-of-concept trial clearly indicates that RSBT-001, is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid (CBDa) reduces cytokine level, and that this cytokine reduction is appropriately transient.

              Lead Product(s): RSBT-001

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RSBT-001

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Synthonics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RS BioTherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RS BioTherapeutics Enters Into License Agreement With Synthonics for First Investigational Compound

              Details:

              Under the license agreement with Synthonics, Inc. for the exclusive, worldwide right for RS BioTherapeutic's lead compound, RSBT-001, as both an alternative and a complement to corticosteroids for the treatment of chronic obstructive pulmonary disease (COPD).

              Lead Product(s): RSBT-001

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RSBT-001

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Synthonics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement May 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY